The Interdisciplinary Annotated Psychedelic Research Bibliography of 2023

The above publications received comments from the researchers we surveyed. Here are further 2023 publications that Michael included in his list.***Jones, G., Herrmann, F., & Wang, E. (2023). Associations between individual hallucinogens and hallucinogen misuse among U.S. Adults who recently initiated hallucinogen use. Addictive behaviors reports, 18, 100513. https://doi.org/10.1016/j.abrep.2023.100513Pettorruso, M., Guidotti, R., d’Andrea, G., De Risio, L., D’Andrea, A., Chiappini, S., Carullo, R., Barlati, S., Zanardi, R., Rosso, G., De Filippis, S., Di Nicola, M., Andriola, I., Marcatili, M., Nicolò, G., Martiadis, V., Bassetti, R., Nucifora, D., De Fazio, P., Rosenblat, J. D., … REAL-ESK Study Group (2023). Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING). Psychiatry Research, 327, 115378. https://doi.org/10.1016/j.psychres.2023.115378Estrade, I., Petit, A. C., Sylvestre, V., Danon, M., Leroy, S., Perrain, R., Vinckier, F., Mekaoui, L., Gaillard, R., Advenier-Iakovlev, E., Mancusi, R. L., Poupon, D., De Maricourt, P., & Gorwood, P. (2023). Early effects predict trajectories of response to esketamine in treatment-resistant depression. Journal of affective disorders, 342, 166–176. https://doi.org/10.1016/j.jad.2023.09.030Ko, K., Carter, B., Cleare, A. J., & Rucker, J. J. (2023). Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis. Neuropsychiatric disease and treatment, 19, 2105–2113. https://doi.org/10.2147/NDT.S426193Donegan, C. J., Daldegan-Bueno, D., Sumner, R., Menkes, D., Evans, W., Hoeh, N., Sundram, F., Reynolds, L., Ponton, R., Cavadino, A., Smith, T., Roop, P., Allen, N., Abeysinghe, B., Svirskis, D., Forsyth, A., Bansal, M., & Muthukumaraswamy, S. (2023). An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1). Pilot and feasibility studies, 9(1), 169. https://doi.org/10.1186/s40814-023-01399-8Bhuiya, N. M. A., Jacobs, R. J., Wang, K., Sun, Y., Nava, B., Sampiere, L., Yerubandi, A., & Caballero, J. (2023). Predictors of Pharmacy Students’ Attitudes About the Therapeutic Use of Psilocybin. Cureus, 15(9), e45169. https://doi.org/10.7759/cureus.45169Walsh, C. A., Gorfinkel, L., Shmulewitz, D., Stohl, M., & Hasin, D. S. (2024). Use of Lysergic Acid Diethylamide by Major Depression Status. JAMA Psychiatry, 81(1), 89-96. Epub 2023 Oct 11. https://doi.org/10.1001/jamapsychiatry.2023.3867Armstrong, S. B., Levin, A. W., Xin, Y., Horan, J. C., Luoma, J., Nagib, P., Pilecki, B., & Davis, A. K. (2023). Differences in attitudes and beliefs about psychedelic-assisted therapy among social workers, psychiatrists, and psychologists in the United States. Journal of Psychedelic Studies, 7(S1), 61-67. https://doi.org/10.1556/2054.2023.00245Harrison, T. R. (2023). Altered stakes: Identifying gaps in the informed consent process for psychedelic-assisted therapy trials. Journal of Psychedelic Studies, 7(S1), 48-60. https://doi.org/10.1556/2054.2023.00267Devenot, N. (2023). TESCREAL hallucinations: Psychedelic and AI hype as inequality engines. Journal of Psychedelic Studies, 7(S1), 22-39. https://doi.org/10.1556/2054.2023.00292Monte, A. A., Schow, N. S., Black, J. C., Bemis, E. A., Rockhill, K. M., & Dart, R. C. (2023). The Rise of Psychedelic Drug Use Associated With Legalization/Decriminalization: An Assessment With the Nonmedical Use of Prescription Drugs Survey. Annals of Emergency Medicine. Advance online publication. https://doi.org/10.1016/j.annemergmed.2023.11.003Friedman, S. F., & Ballentine, G. (2023). Trajectories of sentiment in 11,816 psychoactive narratives. Human Psychopharmacology Clinical and Experimental. Advance online publication. https://doi.org/10.1002/hup.2889Beaussant, Y., Tarbi, E., Nigam, K., Miner, S., Sager, Z., Sanders, J. J., Ljuslin, M., Guérin, B., Thambi, P., Tulsky, J. A., & Agrawal, M. (2023). Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis. Cancer. Advance online publication. https://doi.org/10.1002/cncr.35024Rocha, J. M., Reis, J. A. S., Rossi, G. N., Bouso, J. C., Hallak, J. E. C., & dos Santos, R. G. (2023). Guidelines for Establishing Safety in Ayahuasca and Ibogaine Administration in Clinical Settings. Psychoactives, 2(4), 373-386. https://doi.org/10.3390/psychoactives2040024Orłowski, P., Hobot, J., Ruban, A., Szczypiński, J., & Bola, M. (2023). The relation between naturalistic use of psychedelics and perception of emotional stimuli: An event-related potential study comparing non-users and experienced users of classic psychedelics. Journal of Psychopharmacology. Advance online publication. https://doi.org/10.1177/02698811231216322Marseille, E., Stauffer, C. S., Agrawal, M., Thambi, P., Roddy, K., Mithoefer, M., Bertozzi, S. M., Kahn, J. G. (2023). Group psychedelic therapy: empirical estimates of cost-savings and improved access. Frontiers in Psychiatry, 14. https://doi.org/10.3389/fpsyt.2023.1293243Mian, M. N., Altman, B. R., Low, F., & Earleywine, M. (2023). Development of the Protective Strategies for Psychedelics Scale: A novel inventory to assess safety strategies in the context of psychedelics. Journal of Psychopharmacology. Advance online publication. https://doi.org/10.1177/02698811231214060Nicholas, C. R., Horton, D. M., Malicki, J., Baltes, A., Hutson, P. R., & Brown, R. T. (2023). Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings. Psychedelic Medicine, 1(4), 253-261. https://doi.org/10.1089/psymed.2023.0012Weintraub, M. J., Jeffrey, J. K., Grob, C. S., Ichinose, M. C., Bergman, R. L., Cooper, Z. D., Miklowitz, D. J. (2023). Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development. Psychedelic Medicine, 1(4), 230-240. https://doi.org/10.1089/psymed.2023.0018Penn, A., & Yehuda, R. (2023). Preventing the Gaps in Psychedelic Research from Becoming Practice Pitfalls: A Translational Research Agenda. Psychedelic Medicine, 1(4), 198-209. https://doi.org/10.1089/psymed.2023.0017Harduf, A., Panishev, G., Harel, E. V., Stern, Y., & Salomon, R. (2023). The bodily self from psychosis to psychedelics. Scientific Reports, 13(1), 21209. https://doi.org/10.1038/s41598-023-47600-zSolomon, T. M., Hajduk, M., Majernik, M., Jemison, J., Deschamps, A., Scoggins, J., Kolar, A., Pinheiro, M. A., Dubec, P., Skala, O., Muir, O., Tinkelman, A., Karlin, D. R., & Barrow, R. (2023). Evaluating passive physiological data collection during Spravato treatment. Frontiers in Digital Health, 5. https://doi.org/10.3389/fdgth.2023.1281529Moaddel, R., Farmer, C. A., Yavi, M., Kadriu, B., Zhu, M., Fan, J., Chen, Q., Lehrmann, E., Fantoni, G., De, S., Mazucanti, C. H., Acevedo-Diaz, E. E., Yuan, P., Gould, T. D., Park, L. T., Egan, J. M., Ferrucci, L., & Zarate, C. A. (2023). Cerebrospinal fluid exploratory proteomics and ketamine metabolite pharmacokinetics in human volunteers after ketamine infusion. iScience, 26(12), 108527. https://doi.org/10.1016/j.isci.2023.108527Jollant, F., Demattei, C., Fabbro, P., & Abbar, M. (2023). Clinical predictive factors and trajectories of suicidal remission over 6 weeks following intravenous ketamine for suicidal ideation. Journal of Affective Disorders, 347, 1-7. https://doi.org/10.1016/j.jad.2023.11.043Wirsching, A., Bostoen, T., & Huizink, A. C. (2023). A Psychometric Evaluation of the Dutch Revised Mystical Experience Questionnaire. Journal of Psychoactive Drugs, ahead-of-print. https://doi.org/10.1080/02791072.2023.2272832Kvam, T.-M., Uthaug, M. V., Andersen, K. A. A., Refsum, B. B., Tunstad, P. A., Stewart, L. H., Jacobsen, H. B., & Grønnerød, C. (2023). Epidemiology of classic psychedelic substances: results from a Norwegian internet convenience sample. Frontiers in Psychiatry, 14. https://doi.org/10.3389/fpsyt.2023.1287196Cruz, L., Bienemann, B., Palhano-Fontes, F., Tófoli, L. F., Araújo, D. B., & Mograbi, D. C. (2023). A quantitative textual analysis of the subjective effects of ayahuasca in naïve users with and without depression. Scientific Reports, 13(1), 19635. https://doi.org/10.1038/s41598-023-44193-5Thornton, N. L. R., Black, W., Bognar, A., Dagge, D., Gitau, T., Hua, B., Joks, G., King, J., Lord, A., Scott, E. M., Callander, J. S., Ting, S., & Liu, D. (2023). Establishing an esketamine clinic in Australia: Practical recommendations and clinical guidance from an expert panel. Asia-Pacific Psychiatry, 15(4), e12550. https://doi.org/10.1111/appy.12550Sugiarto, E., Leung, R., & Yuen, J. (2023). Pharmacists’ Perspectives on Psilocybin in Canada. JAPhA Practice Innovations. Advance online publication. https://doi.org/10.1016/j.japhpi.2023.100003Oliveira-Maia, A. J., Morrens, J., Rive, B., Godinov, Y., Cabrieto, J., Perualila, N., Barbreau, S., & Mulhern-Haughey, S. (2023). ICEBERG study: an indirect adjusted comparison estimating the long-term benefit of esketamine nasal spray when compared with routine treatment of treatment-resistant depression in general psychiatry. Frontiers in Psychiatry, 14, 1250980. https://doi.org/10.3389/fpsyt.2023.1250980Stocker, K., Hartmann, M., Ley, L., Becker, A. M., Holze, F., & Liechti, M. E. (2023). The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies. Journal of Psychopharmacology. Advance online publication. https://doi.org/10.1177/02698811231199112Simonsson, O., Goldberg, S. B., Chambers, R., Osika, W., Simonsson, C., & Hendricks, P. S. (2023). Psychedelic use and psychiatric risks. Psychopharmacology. Advance online publication. https://doi.org/10.1007/s00213-023-06478-5Korman, B. A. (2023). The Rising Use of LSD among Business Managers. Substance Use & Misuse, 59(2), 159-166. https://doi.org/10.1080/10826084.2023.2267105Shams, S., Pratt, A. R., Li, S., & Isenbarger, T. (2023). The Evolving Role of History in the Past, Present, and Future of Psychedelic Patenting. History of Pharmacy and Pharmaceuticals, 65(1), 117-130. https://doi.org/10.3368/hopp.65.1.117Johansen, L., Liknaitzky, P., Nedeljkovic, M., & Murray, G. (2023). How psychedelic-assisted therapy works for depression: expert views and practical implications from an exploratory Delphi study. Frontiers in Psychiatry, 14, 1265910. https://doi.org/10.3389/fpsyt.2023.1265910Elias, S., Spivak, S., Alverez, A., Gili Olivares, A., Ferrol, M., & Keenan, J. P. (2023). Self-perception and self-recognition while looking in the mirror on psilocybin. Journal of Psychedelic Studies, 7(2), 129-134. https://doi.org/10.1556/2054.2023.00251Engel, L., Barratt, M., Ferris, J., Puljevic, C., & Winstock, A. (2023). Mescaline, Peyote and San Pedro: Is sustainability important for cacti consumers? Journal of Psychedelic Studies, 7(2), 135-142. https://doi.org/10.1556/2054.2023.00252Bremler, R., Katati, N., Shergill, P., Erritzoe, D., & Carhart-Harris, R. L. (2023). Case analysis of long-term negative psychological responses to psychedelics. Scientific Reports, 13(1), 15998. https://doi.org/10.1038/s41598-023-41145-xGarel, N., Drury, J., Lévesque, J. T., Goyette, N., Lehmann, A., Looper, K., Erritzoe, D., Dames, S., Turecki, G., Rej, S., Richard-Devantoy, S., & Greenway, K. T. (2023). The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression. Frontiers in Psychiatry, 14, 1268832. https://doi.org/10.3389/fpsyt.2023.1268832Barnett, B. S., Arakelian, M., Beebe, D., Ontko, J., Riegal, C., Siu, W. O., Weleff, J., & Pope, H. G. (2023). American Psychiatrists’ Opinions About Classic Hallucinogens and Their Potential Therapeutic Applications: A 7-Year Follow-Up Survey. Psychedelic Medicine. Advance online publication. https://doi.org/10.1089/psymed.2023.0036La Torre, J. T., Mahammadli, M., Faber, S. C., Greenway, K. T., & Williams, M. T. (2023). Expert Opinion on Psychedelic-Assisted Psychotherapy for People with Psychopathological Psychotic Experiences and Psychotic Disorders. International Journal of Mental Health and Addiction. Advance online publication. https://doi.org/10.1007/s11469-023-01149-0Manson, E., Ryding, E., Taylor, W., Peekeekoot, G., Gloeckler, S. G., Allard, P., Johnny, C., Greenway, K. T., & Dames, S. (2023). Indigenous Voices in Psychedelic Therapy: Experiential Learnings from a Community-Based Group Psychedelic Therapy Program. Journal of Psychoactive Drugs, 55(5), 539-548. https://doi.org/10.1080/02791072.2023.2258120Yonezawa, K., Tani, H., Nakajima, S., & Uchida, H. (2023). Development of the Japanese version of the 30‐item Mystical Experience Questionnaire. Neuropsychopharmacology Reports. Advance online publication. https://doi.org/10.1002/npr2.12377Eckernäs, E., Koomen, J., Timmermann, C., Carhart‐Harris, R., Röshammar, D., & Ashton, M. (2023). Optimized infusion rates for N,N‐dimethyltryptamine to achieve a target psychedelic intensity based on a modeling and simulation framework. CPT Pharmacometrics & Systems Pharmacology, 12(10), 1398-1410. https://doi.org/10.1002/psp4.13037Loizaga-Velder, A., Giovannetti, C., Gomez, R. C., Valenzuela, T. E. C., Jaime, G. R. O., Agin-Liebes, G., Marcus, O., & Rush, B. (2023). Therapeutic Effects of Ceremonial Ayahuasca Use for Methamphetamine Use Disorders and Other Mental Health Challenges: Case Studies in an Indigenous Community in Sonora, Mexico. Journal of Psychoactive Drugs, 55(5), 549-557. https://doi.org/10.1080/02791072.2023.2255182Flynn, L. T., & Gao, W.-J. (2023). DNA methylation and the opposing NMDAR dysfunction in schizophrenia and major depression disorders: a converging model for the therapeutic effects of psychedelic compounds in the treatment of psychiatric illness. Molecular Psychiatry, 1-15. https://doi.org/10.1038/s41380-023-02235-4Arkfeld, D. G., Alexopoulos, C., & Gonzales, S. A. B. (2023). Potential Benefits of Psilocybin for Lupus Pain: A Case Report. Current Rheumatology Reviews, 20(1), 97-99. https://doi.org/10.2174/1573397119666230904150750Davis, A. K., Xin, Y., Sepeda, N., & Averill, L. A. (2023). Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico. The American Journal of Drug and Alcohol Abuse, 49(5), 587-596. https://doi.org/10.1080/00952990.2023.2220874Herrmann, Z., Levin, A. W., Cole, S. P., Slabaugh, S., Barnett, B., Penn, A., Jain, R., Raison, C., Rajanna, B., & Jain, S. (2023). Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States. Psychedelic Medicine, 1(3), 139-149. https://doi.org/10.1089/psymed.2023.0030Dubus, Z., Grandgeorge, E., & Verroust, V. (2023). History of the administration of psychedelics in France. Frontiers in Psychology, 14, 1131565. https://doi.org/10.3389/fpsyg.2023.1131565Aday, J. S., Barnett, B. S., Grossman, D., Murnane, K. S., Nichols, C. D., & Hendricks, P. S. (2023). Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry. Psychedelic Medicine, 1(3), 150-165. https://doi.org/10.1089/psymed.2023.0013Ramaekers, J. G., Mallaroni, P., Kloft, L., Reckweg, J. T., Toennes, S. W., van Oorsouw, K., & Mason, N. L. (2023). Altered State of Consciousness and Mental Imagery as a Function of N, N-dimethyltryptamine Concentration in Ritualistic Ayahuasca Users. Journal of Cognitive Neuroscience, 35(9), 1382-1393. https://doi.org/10.1162/jocn_a_02003Kunstler, B. E., Smith, L., Langmead, C. J., Goodwin, D. M., Wright, B., & Hatty, M. A. (2023). “We don’t want to run before we walk”: the attitudes of Australian stakeholders towards using psychedelics for mental health conditions. Public Health Research & Practice, 33(3). https://doi.org/10.17061/phrp3332321Kovacevich, A., Weleff, J., Claytor, B., & Barnett, B. S. (2023). Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD. Journal of Psychoactive Drugs, 55(5), 672-679. https://doi.org/10.1080/02791072.2023.2253538Feng, R., Ching, T. H. W., Bartlett, A. C., La Torre, J. T., & Williams, M. T. (2023). Healing Words: Effects of Psychoeducation on Likelihood to Seek and Refer Psychedelic-Assisted Psychotherapy Among BIPOC Individuals. Journal of Psychoactive Drugs, ahead-of-print, 1-13. https://doi.org/10.1080/02791072.2023.2253535Rush, B., Marcus, O., García, S., Loizaga-Velder, A., Spitalier, A., & Mendive, F. (2023). Ayahuasca Treatment Outcome Project (ATOP): One Year Results from Takiwasi Center and Implications for Psychedelic Science. Journal of Studies on Alcohol and Drugs. https://doi.org/10.15288/jsad.23-00005Zeifman, R. J., Kettner, H., Pagni, B. A., Mallard, A., Roberts, D. E., Erritzoe, D., Ross, S., & Carhart-Harris, R. L. (2023). Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences. Scientific Reports, 13(1), 13645. https://doi.org/10.1038/s41598-023-40856-5Dougherty, R. F., Clarke, P., Atli, M., Kuc, J., Schlosser, D., Dunlop, B. W., Hellerstein, D. J., Aaronson, S. T., Zisook, S., Young, A. H., Carhart-Harris, R., Goodwin, G. M., & Ryslik, G. A. (2023). Psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processing. Psychopharmacology, 1-9. https://doi.org/10.1007/s00213-023-06432-5Palamar, J. J., Rutherford, C., Le, A., & Keyes, K. M. (2023). Seasonal Variation of Use of Common Psychedelics and Party Drugs Among Nightclub/Festival Attendees in New York City. Journal of Psychoactive Drugs, ahead-of-print, 1-8. https://doi.org/10.1080/02791072.2023.2240322Cavarra, M., Mason, N. L., Kuypers, K. P. C., Bonnelle, V., Smith, W. J., Feilding, A., Kryskow, P., & Ramaekers, J. G. (2023). Potential analgesic effects of psychedelics on select chronic pain conditions: A survey study. European Journal of Pain, 28(1), 153-165. https://doi.org/10.1002/ejp.2171Gramling, R., Bennett, E., Curtis, K., Richards, W., Rizzo, D. M., Arnoldy, F., Hegg, L., Porter, J., Honstein, H., Pratt, S., Tarbi, E., Reblin, M., Thambi, P., Agrawal, M. (2023). Developing a Direct Observation Measure of Therapeutic Connection in Psilocybin-Assisted Therapy: A Feasibility Study. Journal of Palliative Medicine, 26(12), 1702-1708. https://doi.org/10.1089/jpm.2023.0189Falkenberg, I., Bitsch, F., Liu, W., Matsingos, A., Noor, L., Vogelbacher, C., Yildiz, C., & Kircher, T. (2023). The effects of esketamine and treatment expectation in acute major depressive disorder (Expect): study protocol for a pharmacological fMRI study using a balanced placebo design. Trials, 24(1), 514. https://doi.org/10.1186/s13063-023-07556-xDowney, A. E., Boyd, M., Chaphekar, A. V., Woolley, J., & Raymond‐Flesch, M. (2023). “But the reality is it’s happening”: A qualitative study of eating disorder providers about psilocybin‐assisted psychotherapy. International Journal of Eating Disorders, 56(11), 2142-2148. https://doi.org/10.1002/eat.24041Kim, A., & Suzuki, J. (2023). Addiction specialists’ attitudes toward psychedelics: A National Survey. American Journal on Addictions, 32(6), 606-609. https://doi.org/10.1111/ajad.13461Boehnke, K. F., Cox, K., Weston, C., Herberholz, M., Glynos, N., Kolbman, N., Fields, C. W., Barron, J., & Kruger, D. J. (2023). Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers. Frontiers in Psychiatry, 14. https://doi.org/10.3389/fpsyt.2023.1224551Teeple, A., Zhdanava, M., Pilon, D., Caron-Lapointe, G., Lefebvre, P., & Joshi, K. (2023). Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance. Current Medical Research and Opinion, 39(8), 1167-1174. https://doi.org/10.1080/03007995.2023.2239045Abrams, S. K., Rabinovitch, B. S., Zafar, R., Aziz, A. S., Cherup, N. P., McMillan, D. W., Nielson, J. L., & Lewis, E. C. (2023). Persons With Spinal Cord Injury Report Peripherally Dominant Serotonin-Like Syndrome After Use of Serotonergic Psychedelics. Neurotrauma Reports, 4(1), 543-550. https://doi.org/10.1089/neur.2023.0022Korman, B. A. (2023). On the mushrooming reports of “quiet quitting”: Employees’ lifetime psilocybin use predicts their overtime hours worked. Journal of Psychoactive Drugs, ahead-of-print(ahead-of-print), 1-10. https://doi.org/10.1080/02791072.2023.2242358Glynos, N. G., Kruger, D. J., Kolbman, N., Boehnke, K., & Lucas, P. (2023). The Relationship Between Naturalistic Psychedelic Use and Clinical Care in Canada. Journal of Psychoactive Drugs, 55(5), 660-671. https://doi.org/10.1080/02791072.2023.2242353Szigeti, B., Nutt, D., Carhart-Harris, R., & Erritzoe, D. (2023). The difference between ‘placebo group’ and ‘placebo control’: a case study in psychedelic microdosing. Scientific Reports, 13(1), 12107. https://doi.org/10.1038/s41598-023-34938-7Husain, M. I., Blumberger, D. M., Castle, D. J., Ledwos, N., Fellows, E., Jones, B. D. M., … & Mulsant, B. H. (2023). Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial. BJPsych Open, 9(4), e134. https://doi.org/10.1192/bjo.2023.535Lawrence, D. W., DiBattista, A. P., & Timmermann, C. (2023). N, N-Dimethyltryptamine (DMT)-Occasioned Familiarity and the Sense of Familiarity Questionnaire (SOF-Q). Journal of Psychoactive Drugs, ahead-of-print(ahead-of-print), 1-13. https://doi.org/10.1080/02791072.2023.2230568Godes, M., Lucas, J., & Vermetten, E. (2023). Perceived key change phenomena of MDMA-assisted psychotherapy for the treatment of severe PTSD: an interpretative phenomenological analysis of clinical integration sessions. Frontiers in Psychiatry, 14, 957824. https://doi.org/10.3389/fpsyt.2023.957824Modlin, N. L., Stubley, J., Maggio, C., & Rucker, J. J. (2023). On Redescribing the Indescribable: Trauma, Psychoanalysis and Psychedelic Therapy. British Journal of Psychotherapy, 39(3), 551-572. https://doi.org/10.1111/bjp.12852Haug, N. A., Wadekar, R., Barry, R., & Sottile, J. (2023). Risk for Ecstasy Use Disorder and Other Substance Use Among International Users of Recreational Ecstasy/Molly/MDMA. Journal of Psychoactive Drugs, ahead-of-print(ahead-of-print), 1-10. https://doi.org/10.1080/02791072.2023.2227960Blond, B. N., & Schindler, E. A. D. (2023). Case report: Psychedelic-induced seizures captured by intracranial electrocorticography. Frontiers in Neurology, 14, 1214969. https://doi.org/10.3389/fneur.2023.1214969Li, I., Fong, R., Hagen, M., & Tabaac, B. (2023). Medical student attitudes and perceptions of psychedelic-assisted therapies. Frontiers in Psychiatry, 14, 1190507. https://doi.org/10.3389/fpsyt.2023.1190507Kruger, D. J., Barron, J., Herberholz, M., & Boehnke, K. F. (2023). Preferences and Support for Psychedelic Policies and Practices Among Those Using Psychedelics. Journal of Psychoactive Drugs, 55(5), 650-659. https://doi.org/10.1080/02791072.2023.2228784Weiss, B., Wingert, A., Erritzoe, D., & Campbell, W. K. (2023). Prevalence and therapeutic impact of adverse life event reexperiencing under ceremonial ayahuasca. Scientific Reports, 13(1), 9438. https://doi.org/10.1038/s41598-023-36184-3Gukasyan, N., Griffiths, R. R., Yaden, D. B., Antoine, D. G., & Nayak, S. M. (2023). Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use. Journal of Psychopharmacology, 37(7), 707-716. https://doi.org/10.1177/02698811231179910Keyes, K. M., & Patrick, M. E. (2023). Hallucinogen use among young adults ages 19–30 in the United States: Changes from 2018 to 2021. Addiction, 118(12), 2449-2454. https://doi.org/10.1111/add.16259Agin-Liebes, G., Nielson, E. M., Zingman, M., Kim, K., Haas, A., Owens, L. T., … & Bogenschutz, M. (2023). Reports of Self-Compassion and Affect Regulation in Psilocybin-Assisted Therapy for Alcohol Use Disorder: An Interpretive Phenomenological Analysis. Psychology of Addictive Behaviors, 1-15. https://doi.org/10.1037/adb0000935Weiss, B., Ginige, I., Shannon, L., Giribaldi, B., Murphy-Beiner, A., Murphy, R., … & Erritzoe, D. (2023). Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression. Psychological Medicine, 1-15. https://doi.org/10.1017/s0033291723001514Yavorsky, C., Ballard, E., Opler, M., Sedway, J., Targum, S. D., & Lenderking, W. (2023). Recommendations for selection and adaptation of rating scales for clinical studies of rapid-acting antidepressants. Frontiers in Psychiatry, 14, 1135828. https://doi.org/10.3389/fpsyt.2023.1135828Lake, S., & Lucas, P. (2023). The Canadian Psychedelic Survey: Characteristics, Patterns of Use, and Access in a Large Sample of People Who Use Psychedelic Drugs. Psychedelic Medicine, 1(2), 98-110. https://doi.org/10.1089/psymed.2023.0002Pleet, M. M., White, J., Zamaria, J. A., & Yehuda, R. (2023). Reducing the Harms of Nonclinical Psychedelics Use Through a Peer-Support Telephone Helpline. Psychedelic Medicine, 1(2), 69-73. https://doi.org/10.1089/psymed.2022.0017Jacobs, E. (2023). Transformative experience and informed consent to psychedelic-assisted psychotherapy. Frontiers in Psychology, 14, 1108333. https://doi.org/10.3389/fpsyg.2023.1108333Breeksema, J. J., Niemeijer, A., Kuin, B., Veraart, J., Vermetten, E., Kamphuis, J., … Schoevers, R. (2023). Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study. Psychopharmacology, 240(7), 1547-1560. https://doi.org/10.1007/s00213-023-06388-6Majdinasab, E., Datta, P., Krutsch, K., Baker, T., & Hale, T. W. (2023). Pharmacokinetics of Ketamine Transfer Into Human Milk. Journal of Clinical Psychopharmacology, 43(5), 407-410. https://doi.org/10.1097/jcp.0000000000001711Makunts, T., Dahill, D., Jerome, L., de Boer, A., & Abagyan, R. (2023). Concomitant medications associated with ischemic, hypertensive, and arrhythmic events in MDMA users in FDA adverse event reporting system. Frontiers in Psychiatry, 14, 1149766. https://doi.org/10.3389/fpsyt.2023.1149766Hietamies, T. M., McInnes, L. A., Klise, A. J., Worley, M. J., Qian, J. J., Williams, L. M., … Levine, S. P. (2023). The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis. Journal of Affective Disorders, 335, 484-492. https://doi.org/10.1016/j.jad.2023.04.141Davis, O. (2023). Henri Michaux’s program for the psychedelic humanities. Frontiers in Psychology, 14, 1152896. https://doi.org/10.3389/fpsyg.2023.1152896Zhdanava, M., Teeple, A., Pilon, D., Shah, A., Caron-Lapointe, G., & Joshi, K. (2023). Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States. Journal of Medical Economics, 26(1), 691-700. https://doi.org/10.1080/13696998.2023.2208993Spriggs, M. J., Murphy-Beiner, A., Murphy, R., Bornemann, J., Thurgur, H., & Schlag, A. K. (2023). ARC: a framework for access, reciprocity and conduct in psychedelic therapies. Frontiers in Psychology, 14, 1119115. https://doi.org/10.3389/fpsyg.2023.1119115Palamar, J. J. (2023). Tusi: a new ketamine concoction complicating the drug landscape. The American Journal of Drug and Alcohol Abuse, 49(5), 546-550. https://doi.org/10.1080/00952990.2023.2207716Romero, O. G. (2023). Cognitive liberty and the psychedelic humanities. Frontiers in Psychology, 14, 1128996. https://doi.org/10.3389/fpsyg.2023.1128996Davis, A. K., Levin, A. W., Nagib, P. B., Armstrong, S. B., & Lancelotta, R. L. (2023). Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD. BMJ Open, 13(5), e068884. https://doi.org/10.1136/bmjopen-2022-068884Zeifman, R. J., Wagner, A. C., Monson, C. M., & Carhart-Harris, R. L. (2023). How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change. Journal of Affective Disorders, 334, 100-112. https://doi.org/10.1016/j.jad.2023.04.105Lewis, B. R., Byrne, K., Hendrick, J., Garland, E. L., Thielking, P., & Beck, A. (2023). Group format psychedelic-assisted therapy interventions: Observations and impressions from the HOPE trial. Journal of Psychedelic Studies, 7(1), 1-11. https://doi.org/10.1556/2054.2022.00222Ching, T. H. W., Grazioplene, R., Bohner, C., Kichuk, S. A., DePalmer, G., D’Amico, E., … Kelmendi, B. (2023). Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial. Frontiers in Psychiatry, 14, 1178529. https://doi.org/10.3389/fpsyt.2023.1178529Weiss, B., Erritzoe, D., Giribaldi, B., Nutt, D. J., & Carhart-Harris, R. L. (2023). A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression. Journal of Psychopharmacology, 37(7), 717-732. https://doi.org/10.1177/02698811231167848Kruger, D. J., Enghoff, O., Herberholz, M., Barron, J., & Boehnke, K. F. (2023). “How Do I Learn More About this?”: Utilization and Trust of Psychedelic Information Sources Among People Naturalistically Using Psychedelics. Journal of Psychoactive Drugs, 55(5), 631-639. https://doi.org/10.1080/02791072.2023.2201263Sjöstedt-Hughes, P. (2023). On the need for metaphysics in psychedelic therapy and research. Frontiers in Psychology, 14, 1128589. https://doi.org/10.3389/fpsyg.2023.1128589Feduccia, A., Agin-Liebes, G., Price, C. M., Grinsell, N., Paradise, S., & Rabin, D. M. (2023). The need for establishing best practices and gold standards in psychedelic medicine. Journal of Affective Disorders, 332, 47–54. https://doi.org/10.1016/j.jad.2023.03.083Evans, J. (2023). ‘More evolved than you’: Evolutionary spirituality as a cultural frame for psychedelic experiences. Frontiers in Psychology, 14, 1103847. https://doi.org/10.3389/fpsyg.2023.1103847Rosenblat, J. D., Leon-Carlyle, M., Ali, S., Husain, M. I., & McIntyre, R. S. (2023). Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects. American Journal of Psychiatry, 180(5), 395-396. https://doi.org/10.1176/appi.ajp.20220835Brett, J., Knock, E., Korthuis, P. T., Liknaitzky, P., Murnane, K. S., Nicholas, C. R., … Stauffer, C. S. (2023). Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder. Frontiers in Psychiatry, 14, 1123424. https://doi.org/10.3389/fpsyt.2023.1123424Kopra, E. I., Ferris, J. A., Winstock, A. R., Kuypers, K. P., Young, A. H., & Rucker, J. J. (2023). Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020. Journal of Psychopharmacology, 37(7), 733-748. https://doi.org/10.1177/02698811231158245Kinderlehrer, D. A. (2023). The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study. International Medical Case Reports Journal, 16, 109-115. https://doi.org/10.2147/imcrj.s395342Kňažek, F., Horák, M., Ocetková, T., Somerlíková, K., Bláhová, B., Plevková, M., … Kočárová, R. (2023). Typology of Users of Psychedelics and Alike Psychoactive Substances in Czechia: Results of the National Online Survey. Journal of Psychoactive Drugs, 55(5), 601-611. https://doi.org/10.1080/02791072.2023.2177908Grimmer, H. J., Tangen, J. M., Freydenzon, A., & Laukkonen, R. E. (2023). The illusion of insight: detailed warnings reduce but do not prevent false “Aha!” moments. Cognition & Emotion, 37(2), 329-338. https://doi.org/10.1080/02699931.2023.2187352Lewis, C. R., Tafur, J., Spencer, S., Green, J. M., Harrison, C., Kelmendi, B., … Cahn, B. R. (2023). Pilot study suggests DNA methylation of the glucocorticoid receptor gene (NR3C1) is associated with MDMA-assisted therapy treatment response for severe PTSD. Frontiers in Psychiatry, 14, 959590. https://doi.org/10.3389/fpsyt.2023.959590Mathai, D. S., Nayak, S. M., Yaden, D. B., & Garcia-Romeu, A. (2023). Reconsidering “dissociation” as a predictor of antidepressant efficacy for esketamine. Psychopharmacology, 240(4), 827-836. https://doi.org/10.1007/s00213-023-06324-8Perkins, D., Ruffell, S. G. D., Day, K., Rubiano, D. P., & Sarris, J. (2023). Psychotherapeutic and neurobiological processes associated with ayahuasca: A proposed model and implications for therapeutic use. Frontiers in Neuroscience, 16, 879221. https://doi.org/10.3389/fnins.2022.879221Modlin, N. L., Miller, T. M., Rucker, J. J., Kirlic, N., Lennard-Jones, M., Schlosser, D., … Aaronson, S. T. (2023). Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation. Journal of Affective Disorders, 326, 18-25. https://doi.org/10.1016/j.jad.2023.01.077Singh, B., Vande Voort, J. L., Riva-Posse, P., Pazdernik, V. M., Frye, M. A., & Tye, S. J. (2023). Ketamine-Associated Change in Anhedonia and mTOR Expression in Treatment-Resistant Depression. Biological Psychiatry, 93(12), e65-e68. https://doi.org/10.1016/j.biopsych.2022.10.007Gukasyan, N., & Narayan, S. K. (2023). Menstrual Changes and Reversal of Amenorrhea Induced by Classic Psychedelics: A Case Series. Journal of Psychoactive Drugs, ahead-of-print(ahead-of-print), 1-6. https://doi.org/10.1080/02791072.2022.2157350Correll, C. U., Solmi, M., Cortese, S., Fava, M., Højlund, M., Kraemer, H. C., … Kane, J. M. (2023). The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents. World Psychiatry, 22(1), 48-74. https://doi.org/10.1002/wps.21056Forstmann, M., Kettner, H. S., Sagioglou, C., Irvine, A., Gandy, S., Carhart-Harris, R. L., & Luke, D. (2023). Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness. Journal of Psychopharmacology, 37(1), 93-106. https://doi.org/10.1177/02698811221146356van Vugt, A. S., Zijlmans, J., Lindauer, R., & van Dam, L. (2023). MDMA-assisted psychotherapy with adolescents suffering from PTSD: Do or don’t? a qualitative study with youth, parents, and clinicians. Drug Science Policy and Law, 9. https://doi.org/10.1177/20503245231198477Brandt, J. (2023). A roadmap for psychedelic pharmacy in Canada: A proposed policy and operations approach for controlled access to select psychedelics for treatment of mental illness. Drug Science Policy and Law, 9, 20503245231170340. https://doi.org/10.1177/20503245231170340Tsang, V. W. L., Tao, B., Dames, S., Walsh, Z., & Kryskow, P. (2023). Safety and tolerability of intramuscular and sublingual ketamine for psychiatric treatment in the Roots To Thrive ketamine-assisted therapy program: a retrospective chart review. Therapeutic Advances in Psychopharmacology, 13. https://doi.org/10.1177/20451253231171512D’Arienzo, A., & Samorini, G. (2023). Italian psychedelic therapies of the past century: An historical overview. Drug Science Policy and Law, 9, 20503245231179687. https://doi.org/10.1177/20503245231179687Rajwani, K. (2023). The “Third” Eye: Ethics of Video Recording in the Context of Psychedelic-Assisted Therapy. Canadian Journal of Bioethics, 6(3-4), 8. https://doi.org/10.7202/1108000arHoloyda, B. J. (2022). Malpractice and Other Civil Liability in Psychedelic Psychiatry. Psychiatric Services, 74(1), 92-95. https://doi.org/10.1176/appi.ps.20220528Hadar, A., David, J., Shalit, N., Roseman, L., Gross, R., Sessa, B., & Lev-Ran, S. (2023). The Psychedelic Renaissance in Clinical Research: A Bibliometric Analysis of Three Decades of Human Studies with Psychedelics. Journal of Psychoactive Drugs, 55(1), 1-10. https://doi.org/10.1080/02791072.2021.2022254Andersson, M., Persson, M., & Kjellgren, A. (2023). Psychoactive substances as a last resort—a qualitative study of self-treatment of migraine and cluster headaches. Harm Reduction Journal, 14(1), 60. https://doi.org/10.1186/s12954-017-0186-6Baggott, M. J. (2023). Learning about STP – A Forgotten Psychedelic from the Summer of Love. History of Pharmacy and Pharmaceuticals, 65(1), 93–116. https://doi.org/10.3368/hopp.65.1.93Pagán, A. F., Lex, C., Soares, J. C., & Meyer, T. D. (2023). Medical students’ attitudes and beliefs toward psilocybin: Does terminology and personal experience with psychedelics matter? Psychedelic Medicine, 1(3), 130–138. https://doi.org/10.1089/psymed.2023.0022Price, R. B., Wallace, M. L., Mathew, S. J., & Howland, R. H. (2023). One-Year Outcomes Following Intravenous Ketamine Plus Digital Training Among Patients with Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical Trial. JAMA network open, 6(5), e2312434. https://doi.org/10.1001/jamanetworkopen.2023.12434Sandbrink, J. D., Johnson, K., Gill, M., Yaden, D. B., Savulescu, J., Hannikainen, I. R., & Earp, B. D. (in press). Strong bipartisan support for controlled psilocybin use as treatment or enhancement in a representative sample of US Americans: need for caution in public policy persists. AJOB Neuroscience, in press.Doll, Agnieszka. (in press). Making ‘Medical”: How Psychedelics Are Becoming Legal in Canada. Dalhousie Law Journal, in press.Batievsky, D., Weiner, M., Kaplan, S. B., Thase, M. E., Maglione, D. N., & Vidot, D. C. (2023). Ketamine-assisted psychotherapy treatment of chronic pain and comorbid depression: a pilot study of two approaches. Frontiers in pain research (Lausanne, Switzerland), 4, 1127863. https://doi.org/10.3389/fpain.2023.1127863Rieser, N. M., Gubser, L. P., Moujaes, F., Duerler, P., Lewis, C. R., Michels, L., Vollenweider, F. X., & Preller, K. H. (2023). Psilocybin-induced changes in cerebral blood flow are associated with acute and baseline inter-individual differences. Scientific reports, 13(1), 17475. https://doi.org/10.1038/s41598-023-44153-zLi, A., Liu, H., Lei, X., He, Y., Wu, Q., Yan, Y., Zhou, X., Tian, X., Peng, Y., Huang, S., Li, K., Wang, M., Sun, Y., Yan, H., Zhang, C., He, S., Han, R., Wang, X., & Liu, B. (2023). Hierarchical fluctuation shapes a dynamic flow linked to states of consciousness. Nature communications, 14(1), 3238. https://doi.org/10.1038/s41467-023-38972-xMoujaes, F., Rieser, N. M., Phillips, C., de Matos, N. M. P., Brügger, M., Dürler, P., Smigielski, L., Stämpfli, P., Seifritz, E., Vollenweider, F. X., Anticevic, A., & Preller, K. H. (2023). Comparing Neural Correlates of Consciousness: From Psychedelics to Hypnosis and Meditation. Biological psychiatry. Cognitive neuroscience and neuroimaging, S2451-9022(23)00174-X. Advance online publication. https://doi.org/10.1016/j.bpsc.2023.07.003Ruffini, G., Damiani, G., Lozano-Soldevilla, D., Deco, N., Rosas, F. E., Kiani, N. A., Ponce-Alvarez, A., Kringelbach, M. L., Carhart-Harris, R., & Deco, G. (2023). LSD-induced increase of Ising temperature and algorithmic complexity of brain dynamics. PLoS Computational Biology, 19(2), e1010811. https://doi.org/10.1371/journal.pcbi.1010811Luppi, A. I., Vohryzek, J., Kringelbach, M. L., Mediano, P. A. M., Craig, M. M., Adapa, R., Carhart-Harris, R. L., Roseman, L., Pappas, I., Peattie, A. R. D., Manktelow, A. E., Sahakian, B. J., Finoia, P., Williams, G. B., Allanson, J., Pickard, J. D., Menon, D. K., Atasoy, S., & Stamatakis, E. A. (2023). Distributed harmonic patterns of structure-function dependence orchestrate human consciousness. Communications Biology, 6(1), 117. https://doi.org/10.1038/s42003-023-04474-1Herzog, R., Mediano, P. A. M., Rosas, F. E., Lodder, P., Carhart-Harris, R., Perl, Y. S., Tagliazucchi, E., & Cofre, R. (2023). A whole-brain model of the neural entropy increase elicited by psychedelic drugs. Scientific reports, 13(1), 6244. https://doi.org/10.1038/s41598-023-32649-7Luppi, A. I., Hansen, J. Y., Adapa, R., Carhart-Harris, R. L., Roseman, L., Timmermann, C., Golkowski, D., Ranft, A., Ilg, R., Jordan, D., Bonhomme, V., Vanhaudenhuyse, A., Demertzi, A., Jaquet, O., Bahri, M. A., Alnagger, N. L. N., Cardone, P., Peattie, A. R. D., Manktelow, A. E., de Araujo, D. B., … Stamatakis, E. A. (2023). In vivo mapping of pharmacologically induced functional reorganization onto the human brain’s neurotransmitter landscape. Science advances, 9(24), eadf8332. https://doi.org/10.1126/sciadv.adf8332Bedford, P., Hauke, D. J., Wang, Z., Roth, V., Nagy-Huber, M., Holze, F., Ley, L., Vizeli, P., Liechti, M. E., Borgwardt, S., Müller, F., & Diaconescu, A. O. (2023). The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity. Neuropsychopharmacology, 48(8), 1175–1183. https://doi.org/10.1038/s41386-023-01574-8Tolle, H. M., Farah, J. C., Mallaroni, P., Mason, N. L., Ramaekers, J. G., & Amico, E. (2023). The Unique Neural Signature of Your Trip: Functional Connectome Fingerprints of Subjective Psilocybin Experience. Network Neuroscience, 1-54. https://doi.org/10.1162/netn_a_00349Delli Pizzi, S., Chiacchiaretta, P., Sestieri, C., Ferretti, A., Tullo, M. G., Della Penna, S., Martinotti, G., Onofrj, M., Roseman, L., Timmermann, C., Nutt, D. J., Carhart-Harris, R. L., & Sensi, S. L. (2023). LSD-induced changes in the functional connectivity of distinct thalamic nuclei. NeuroImage, 283, 120414. https://doi.org/10.1016/j.neuroimage.2023.120414



Source link